Pathway Genomics Corporation Qui Tam Action – $4.1 Million Settlement

Case name: United States of America ex rel. Gipson v. Pathway Genomics Corp.
Case type: Whistleblower & Qui Tam
Filed in: [U.S. District Court for the Southern District of California]
Docket: [Case No. 3:14-cv-01919]

Case Summary

In December 2015, Sanford Heisler Sharp and the U.S. Government settled a whistleblower action under the False Claims Act (“FCA”) and the Anti-Kickback Statute with San Diego-based genetic testing giant Pathway Genomics Corporation (“Pathway”).

As part of the settlement, Pathway agreed to pay the U.S. Government, 28 states and the District of Columbia $4.1 million. The Relator, who was represented by Sanford Heisler Sharp and Aashish Y. Desai of the Desai Law Firm, P.C., received a portion of the settlement.

The case alleged that Pathway, which provides lab-based genetic screening tests for a variety of conditions, violated its government contracts by offering physicians and medical groups a reimbursement program that induced and rewarded them for referring their patients to Pathway.

The states involved in the settlement included: California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Indiana, Iowa, Louisiana, Maryland, Massachusetts, Michigan, Minnesota, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Oklahoma, Rhode Island, Tennessee, Texas, Virginia, Washington, Wisconsin, as well as the District of Columbia.

News Coverage

Attorneys Involved in the Case

Press Releases